Estimating the Harms of Nicotine-Containing Products Using the MCDA Approach
David Nutt(Imperial College London), David Sweanor(University of Ottawa), Martin Dockrell(Action on Smoking and Health), Lawrence D. Phillips(London School of Economics and Political Science), Kgosi Letlape(South African Medical Association), Riccardo Polosa(University of Catania), H. Valerie Curran(MRC Cancer Unit), Anders Milton(Milton District Hospital), J. Michael Ramsey(St George's, University of London), Jonathan Foulds(Pennsylvania State University), Karl Fagerström(WSP Sverige (Sweden)), David J.K. Balfour(University of the Southern Caribbean)
Cited by 442
Related Papers
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
|Psychopharmacology|2017|969
Neural correlates of the LSD experience revealed by multimodal neuroimaging
|Proceedings of the National Academy of Sciences|2016|880
Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review
|JAMA Psychiatry|2016|856
Guidelines on nicotine dose selection for in vivo research
|Psychopharmacology|2006|831
Treatment strategies for allergy and asthma
|Nature reviews. Immunology|2008|687